NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Abeona Therapeutics Inc. (ABEO) Stock Analysis

Abeona Therapeutics Inc. (ABEO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ABEO

$6.00

+$0.07 (+1.18%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABEO with… →

ABEO Key Statistics

As of Sep 4, 2026
Trading
Open
$5.89
Previous Close
$5.93
Day's Range
5.85–6.02
52-Week Range
4.00–7.65
Volume
866.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.32
Valuation
Market Cap
$343.10M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
13.44
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.21
Financials (FY)
Revenue (FY)
$5.82M
Net Income (FY)
$71.18M
Profit marginThe share of revenue left as profit after all costs and taxes.
−246.42%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
57.18M
1-Year Return
−12.54%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
1.39M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ABEO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+13.85%
2025−5.39%
2024+11.18%
2023+62.66%
2022−63.76%
2021−78.34%
2020−51.99%
2019−54.20%
2018−54.95%
2017+226.80%
2016 (partial year)+32.15%

As of September 4, 2026.

ABEO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$5.82M$71.18M1223.1%
2024$0.00−$63.73M—
2023$3.50M−$54.19M−1548.2%
2022$1.41M−$39.70M−2807.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$5.82M$2.40M−$89.45M$71.18M1223.1%
2024$0.00$0.00−$64.21M−$63.73M—
2023$3.50M$1.90M−$48.20M−$54.19M−1548.2%
2022$1.41M$964.00K−$45.26M−$39.70M−2807.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ABEO Valuation vs Biotechnology Median

Median of 656 stocks
MetricABEOBiotechnology medianvs median
P/S ratio13.4415.2612% below
Profit margin−246.42%0.00%246.4 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Abeona Therapeutics Inc. (ABEO) carries a market capitalisation of $343.10M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 226 employees.

ABEO last closed at $6.00 on September 4, 2026. That is +$0.07 (+1.18%) against the previous close. Over the past 52 weeks the price has ranged from $4.00 to $7.65. The latest close sits 50% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $5.82M. The same year closed with net income of $71.18M. The reported profit margin is −246.42%. That is 246.4 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.21.

Across the 4 fiscal years on file, revenue moves from $1.41M in 2022 to $5.82M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 13.44. On price-to-sales that is 11.92% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −12.54%. Measured over 10 years, that is −25.36% a year compounded. Beta against the wider market is reported at 1.32. Annualized volatility over the trailing 10 years is 90.41%.

Growth & Income

The record shows no dividend for ABEO.

So far in 2026 the price is +13.85%. The strongest complete calendar year on file is 2017 at +226.80%; the weakest is 2021 at −78.34%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Abeona Therapeutics Inc. (ABEO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Abeona Therapeutics Inc. ABEO $343.10M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Abeona Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Visit website →